Gregory Thomas Bourne

USPTO Granted Patents = 20 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 6.6

ph-index = 11

Forward Citations = 226(Granted Patents)

Location History:

Coopers Plains, AU (2009)
Jindalee, AU (2017 - 2020)
Newark, CA (US) (2023)
Brisbane, AU (2019 - 2024)

Company Filing History:

18 out of 32

Protagonist Therapeutics, Inc.

patents

1 out of 340

The University of Queensland

patents

1 out of 1

Protaganist Therapeutics, Inc.

patent

4. 1 out of 410

Janssen Biotech, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12269856 - Hepcidin analogues and uses thereof (2025-04-08),

2. 12234300 - Conjugated hepcidin mimetics (2025-02-25),

3. 11884748 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2024-01-30),

4. 11845808 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2023-12-19),

5. 11807674 - Hepcidin analogues and uses thereof (2023-11-07),

6. 11753443 - Conjugated hepcidin mimetics (2023-09-12),

7. 11472842 - Analogues of hepcidin mimetics with improved in vivo half lives (2022-10-18),

8. 10941183 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2021-03-09),

9. 10787490 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2020-09-29),

10. 10729676 - Opioid agonist peptides and uses thereof (2020-08-04),

11. 10501515 - Hepcidin analogues and uses thereof (2019-12-10),

12. 10442846 - Hepcidin analogues and uses thereof (2019-10-15),

13. 10278957 - Opioid agonist peptides and uses thereof (2019-05-07),

14. 10196424 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2019-02-05),

15. 10035824 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2018-07-31),

Title: Gregory Thomas Bourne: Innovator in Hepcidin Analogues

Introduction: Gregory Thomas Bourne is an esteemed inventor based in Brisbane, Australia, recognized for his significant contributions to the field of biomedical innovations. With a remarkable portfolio encompassing 20 patents, Bourne has made notable advancements that aim to address critical health issues.

Latest Patents: Among his latest inventions are groundbreaking patents focused on hepcidin analogues. The first, titled "Hepcidin analogues and uses thereof," details peptide analogues and their application in the treatment and prevention of diseases related to iron overload, such as hereditary hemochromatosis and iron-loading anemias. The second, "Conjugated hepcidin mimetics," presents hepcidin analogues that boast improved in vivo half-lives, alongside innovative pharmaceutical compositions and methods for their use.

Career Highlights: Gregory Bourne has held pivotal roles at prestigious organizations, including Protagonist Therapeutics, Inc. and The University of Queensland. His work in these institutions has significantly propelled research and development in therapeutic treatments, particularly pertaining to iron modulation in the human body.

Collaborations: Throughout his career, Bourne has collaborated with notable colleagues, including Brian Troy Frederick and Ashok Bhandari. These partnerships have enhanced the breadth of his research, facilitating advancements in the understanding and treatment of various conditions.

Conclusion: Gregory Thomas Bourne exemplifies the spirit of innovation through his dedicated work in the field of hepcidin analogues. His contributions not only advance scientific knowledge but also hold the potential to improve the lives of countless individuals affected by iron-related disorders.

This text is generated by artificial intelligence and may not be accurate.